MARKET WIREReuters • 3h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
Why CTSO Stock dropped -16.03% Today — RQD Quant Desk Flash
$4.40 -16.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.26
Cytosorbents Corporation (CTSO) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $13.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CTSO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CTSO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Cytosorbents Corporation (NASDAQ: CTSO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $4.40 (-16.03% 1D, market cap $13.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTSO ranks #1012 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CTSO compare to CNSY and GUTS in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), CTSO carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 71.5%, and ROIC of -35.0%. By comparison, CNSY (Cerenome Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M) and GUTS (Fractyl Health Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M). Among the 5-stock peer group, CTSO leads on earnings multiple (N/A) while CTSO leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CTSO?
▼
Per CTSO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001175151), Cytosorbents Corporation generated $37.1M in revenue (+4.1% YoY), -$8.2M in net income, and -$12.5M in free cash flow against $44.2M in total assets and $16.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.26 (-3.08%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (21/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-16.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTSO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (21/100 Composite)
🔍 WHY CTSO SCORES 21/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Macro Regime Fit+5/20 pts (24% of score)
FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 47.9 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.79+8.4% Next Q
15
Q2 (-2Q)Grade E$4.11+28.2% Next Q
16
Q3 (-1Q)Grade E$5.27-16.5% Next Q
18
CurrentGrade E$4.40-11.6% Hist 90D α
21
Trajectory: E (15) → E (21)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CTSO Turnaround Squeeze
While CTSO currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.30) and Max Pain ($4.62) forces dealer call-delta covering toward $17.85.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTSO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CTSO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CTSO Stock dropped -16.03% Today — RQD Quant Desk Flash
Cytosorbents Corporation (CTSO) dropped -16.03% to $4.40, trading at 11% of its 52-week range ($2.84 – $17). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 11% of its 52-week range ($2.84 – $17) with RSI-14 at 47.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.40 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 71.5% gross margin and $0 annual free cash flow.
Live CTSO Headlines & Catalysts
MARKET WIREReuters • 3h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
MARKET WIREReuters • 4h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 6h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 8h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 8h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 10h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 11h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTSO)
- ✓Walkthrough of CTSO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CTSO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -63.93%▼ DESCENDING CHANNEL
2026-10-30O $4.39H $4.70L $4.35C $4.40VOL 24.1K
RES: $6.53SUP: $1.99SMA50: $5.30SMA200: $9.49
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CTSO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CTSO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CTSO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CTSO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTSO)
Health Care Rank #1012 of 1016
⚔️ CNSY vs CTSO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CTSO vs. CNSY, GUTS, SINT, PAVM)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Cytosorbents Corporation (CTSO) ranks #1012 by composite RQD confidence (21/100, grade E) and #864 by equity capitalization ($13.9M). Within this direct 5-issuer industry benchmark cohort, CTSO leads on earnings valuation at N/A trailing P/E, while CTSO leads on capital efficiency and profitability with -35.0% ROIC and 71.5% gross margin. GUTS currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with CTSO at 21/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CTSO
ACTIVE
Cytosorbents Corporation | E | 21/100 | — | 71.5% | -35.0% | -16.03% | $13.9M | Benchmark Subject |
| CNSY Cerenome Inc. | D- | 36/100 | — | — | -35.0% | 0.00% | $13.2M | /cnsy-vs-ctso → |
| GUTS Fractyl Health Inc. | D+ | 52/100 | — | — | -35.0% | +11.40% | $13.2M | /guts-vs-ctso → |
| SINT SiNtx Technologies Inc. | D- | 37/100 | — | 45.3% | -35.0% | -1.15% | $13.0M | /sint-vs-ctso → |
| PAVM PAVmed Inc. | E | 31/100 | — | -30.0% | -35.0% | -5.29% | $15.8M | /pavm-vs-ctso → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001175151In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cytosorbents Corporation (CTSO) reported GAAP revenue of $37.1M (+4.1% vs. FY2024 revenue of $35.6M ) , GAAP net income of -$8.2M, operating cash flow of -$12.4M, and free cash flow of -$12.5M (+14.8% YoY). On the balance sheet, CTSO closed FY2025 with $44.2M in total assets against $16.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $37.1M | -$8.2M | -$12.4M | -$12.5M | $44.2M | $16.7M |
| FY2024 (FY) | 2024-12-31 | $35.6M | -$20.7M | -$14.4M | -$14.7M | $47.4M | $14.0M |
| FY2023 (FY) | 2023-12-31 | $0 | -$29.2M | -$21.7M | -$21.7M | — | — |
3. CTSO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CTSO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Cytosorbents Corporation (NASDAQ: CTSO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $4.40 (-16.03% 1D, market cap $13.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTSO ranks #1012 in composite RQD confidence.
How does CTSO compare to CNSY and GUTS in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), CTSO carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 71.5%, and ROIC of -35.0%. By comparison, CNSY (Cerenome Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M) and GUTS (Fractyl Health Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M). Among the 5-stock peer group, CTSO leads on earnings multiple (N/A) while CTSO leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CTSO?
Per CTSO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001175151), Cytosorbents Corporation generated $37.1M in revenue (+4.1% YoY), -$8.2M in net income, and -$12.5M in free cash flow against $44.2M in total assets and $16.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CTSO trading relative to its 50-day, 200-day, and 52-week technical levels?
CTSO last traded at $4.40 (-16.03% on volume of 48,307 shares), positioning the stock -16.98% below its 50-day simple moving average ($5.30) and -53.64% below its 200-day simple moving average ($9.49). Across its 52-week range of $2.84 to $17.00, CTSO sits at the 11.0% percentile with a 14-day RSI of 47.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.85 to $4.95).
CTSO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CTSO stock moving today?
Why CTSO Stock dropped -16.03% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.